Literature DB >> 24367174

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women.

Amit V Patil1, Rahul S Bhamre2, Rajeev Singhai3, Mukund B Tayade4, Vinayak W Patil3.   

Abstract

OBJECTIVE: To determine the expressions and relationship between estrogen receptors (ERs) and progesterone receptors (PgRs) in breast cancer in Indian women. PARTICIPANTS: Surgically removed breast cancer tissues were collected from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, taking (n = 300) cases of infiltrating duct cancer of Indian women after radical mastectomy and lumpectomy; the age- and menopausal-related subgroups satisfied this requirement. MEASUREMENTS: Statistical significance was calculated by the likelihood ratio test; relative risk served to check for significant differences. Relapse-free interval probabilities were calculated according to Kaplan and Meier, with Cox-Mantel test comparing survival functions and P values.
RESULTS: We observed that only in middle-aged postmenopausal patients bearing pT2 tumors were ER and PgR receptors shown to have a prognostic significance with the lowest tested cutoff value being 5 fmol/mg.
CONCLUSION: Immunohistochemistry analysis has been shown to be a prognostic factor for patients with breast cancer; the major aim of determining the ER receptor status is to assess predictive response to hormonal therapy.

Entities:  

Keywords:  hormone receptors; immunohistochemistry; prognostic cancer tissue biomarkers; steroid receptors

Year:  2011        PMID: 24367174      PMCID: PMC3846641          DOI: 10.2147/BCTT.S17892

Source DB:  PubMed          Journal:  Breast Cancer (Dove Med Press)        ISSN: 1179-1314


  12 in total

Review 1.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

Authors:  A Goldhirsch; J H Glick; R D Gelber; A S Coates; H J Senn
Journal:  J Clin Oncol       Date:  2001-09-15       Impact factor: 44.544

2.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

3.  Estrogen and progesterone receptor isoforms: clinical significance in breast cancer.

Authors:  Suzanne Aw Fuqua; Yukun Cui
Journal:  Breast Cancer Res Treat       Date:  2004       Impact factor: 4.872

4.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

Review 5.  Regulation of steroid hormone receptor activity.

Authors:  T G Muldoon
Journal:  Endocr Rev       Date:  1980       Impact factor: 19.871

6.  Steroid receptor levels in breast cancer. Relationships with age and menopausal status.

Authors:  N Wilking; L E Rutqvist; B Nordenskjöld; L Skoog
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

7.  Steroid-hormone receptors in breast cancer.

Authors:  J L Wittliff
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

8.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.

Authors:  M Dowsett; J Houghton; C Iden; J Salter; J Farndon; R A'Hern; R Sainsbury; M Baum
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

9.  Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.

Authors:  S M Thorpe; C Rose; B B Rasmussen; H T Mouridsen; T Bayer; N Keiding
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

10.  Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Authors:  Mitch Dowsett; Craig Allred; Jill Knox; Emma Quinn; Janine Salter; Chris Wale; Jack Cuzick; Joan Houghton; Norman Williams; Elizabeth Mallon; Hugh Bishop; Ian Ellis; Denis Larsimont; Hironobu Sasano; Pauline Carder; Antonio Llombart Cussac; Fiona Knox; Valerie Speirs; John Forbes; Aman Buzdar
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.